Polaris Pharmaceuticals-KY Announces Audit Committee Member Changes
NQ Score
50/100
AI Summary (NQ-processed)
Polaris Pharmaceuticals-KY (6550) announced changes to its Audit Committee members on May 15, 115 (2026). The changes are due to the full re-election of directors, including independent directors, at the company's 2026 Annual General Meeting. The previous term for the independent directors was from September 26, 112 (2023) to June 11, 115 (2026). Zhao Ying-Cheng, an independent director, has been re-appointed. New independent directors appointed are Zhang Yi-Fang (Vice President of Mackay Taitung Branch), Zhang Zhi-Gang (CEO of Zhongen Biomedical), and Di Shi-Jie (Associate Professor at the University of Hong Kong). Zhao Ying-Cheng's brief biography is listed as former TSMC Plant Manager.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What is the company code for Polaris Pharmaceuticals-KY?
- A: The company code is 6550.
- Q: What was the reason for the change in the Audit Committee members?
- A: The change was due to the full re-election of directors, including independent directors, at the company's 2026 Annual General Meeting.
- Q: Who are the newly appointed independent directors?
- A: The newly appointed independent directors are Zhao Ying-Cheng, Zhang Yi-Fang, Zhang Zhi-Gang, and Di Shi-Jie.
- Q: What are the professional backgrounds of the new independent directors?
- A: Zhao Ying-Cheng is listed as a former TSMC Plant Manager. Zhang Yi-Fang is the Vice President of Mackay Taitung Branch. Zhang Zhi-Gang is the CEO of Zhongen Biomedical. Di Shi-Jie is an Associate Professor at the University of Hong Kong.
- Q: What was the previous term for the independent directors?
- A: The previous term was from September 26, 2023, to June 11, 2026.